SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 325.51 |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 130.16 |
| Book Value / Share | 1.32 |
| Price / Book | n/a |
| NCAV ($M) | 73.51 |
| NCAV / Share | 0.74 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.30 |
| Return on Assets (ROA) | -0.28 |
| Return on Equity (ROE) | -0.32 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.86 |
| Current Ratio | 1.86 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 187.59 |
| Assets | 244.25 |
| Liabilities | 114.08 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Biotechnology Value Fund L P | 19.70 | 33.98 | |
| 13G/A | AFFiRiS AG | 6.66 | -2.18 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 7,893 | 60,973 | 12.95 | |
| 10,885 | 59,610 | 18.26 | |
| 13,251 | 54,862 | 24.15 | |
| 14,601 | 95,738 | 15.25 | |
| 13,274 | 82,376 | 16.11 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ACET – Adicet Bio, Inc. | ACRV – Acrivon Therapeutics, Inc. |
| ADMA – ADMA Biologics, Inc. |
Financial data and stock pages provided by
Fintel.io